Contact Us

Yes. CMAS rescue experiments are well-established for glycobiology research: • Construct design: use a codon-modified CMAS sequence with a small C-terminal tag (FLAG, HA). CMAS has the canonical nucleotide sugar synthase architecture — preserve protein integrity. • Catalytically-dead rescue: active site residue mutations abolish CMP-Neu5Ac synthesis activity. • Functional readout: rescue should restore cellular sialylation measured by SNA/MAA lectin staining. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

The choice depends on whether you are studying CLK4 (CDC-like kinase 4)'s role as a splicing factor kinase or its functions in alternative splicing regulation and emerging cancer applications. The Knockout line is the standard tool for asking whether CLK4 is required for these processes — CLK family (CLK1-4) are dual-specificity kinases that phosphorylate serine/arginine (SR) proteins (SRSF1-12) on the RS domain, regulating SR protein localization (nuclear speckle release) and splicing factor activity; CLK4 is the most recently characterized CLK family member. Overexpression is useful for studying CLK4 gain-of-function effects. Important consideration: CLK family (CLK1, CLK2, CLK3, CLK4) members share substantial substrate scope — single CLK4 knockout may show modest phenotypes if other CLKs compensate. Rescue with wild-type or kinase-dead CLK4 is the standard specificity control. The knockout is a critical specificity tool for CLK inhibitors (TG003, T-025, T-039, SM08502/lociletum-emerging) in development for cancer (myeloid malignancies, breast cancer) and Down syndrome (DYRK1A/CLK family inhibition).

Yes. CLK4 rescue experiments require attention to dual-specificity kinase architecture: • Construct design: use a codon-modified CLK4 sequence with a small C-terminal tag (FLAG, HA). CLK4 has N-terminal RS domain (substrate recognition), central kinase domain — preserve all elements. • Kinase-dead rescue: ATP-binding lysine mutation abolishes catalytic activity. • Functional readout: rescue should restore SR protein phosphorylation patterns. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

The choice depends on whether you are studying CACNB1 (Cavβ1)'s role as a voltage-gated calcium channel β-subunit or modeling its functions in skeletal muscle and emerging biology. The Knockout line is the standard tool for asking whether CACNB1 is required for these processes — CACNB1 (β1) is one of four Cav β-subunit paralogs (β1-β4) that bind the α1 pore-forming subunits of voltage-gated calcium channels (Cav1, Cav2 families), regulating channel trafficking to the plasma membrane and gating properties; CACNB1 is principally expressed in skeletal muscle. Overexpression is useful for studying CACNB1 in heterologous expression contexts. Important consideration: Cav β-subunit family (CACNB1-CACNB4) members share substantial functional overlap — single CACNB1 knockout may show modest phenotypes if other Cav βs compensate; CACNB1 is principally functional in skeletal muscle, so HAP1 is not the physiological context but supports biochemical studies. Rescue with wild-type CACNB1 is the standard specificity control. The knockout is valuable for studying Cav β-subunit biology in heterologous expression contexts; physiological Cav channel research requires appropriate excitable cell models.

Yes. CACNB1 rescue experiments require attention to Cav β-subunit architecture: • Construct design: use a codon-modified CACNB1 sequence with a small C-terminal tag (FLAG, HA). CACNB1 has GK and SH3 domains for α1-subunit binding — preserve all elements. • α1-binding-deficient rescue: GK domain mutations disrupt α1-AID binding for partnership-deficient rescue. • Cav β paralog studies: rescue interpretation considers other CACNB expression. • Functional readout: rescue should restore Cav channel surface expression and gating in heterologous α1-expressing systems. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

The choice depends on whether you are studying COPS6 (CSN6, COP9 signalosome subunit 6)'s role as a component of the COP9 signalosome or modeling its emerging functions in cancer biology. The Knockout line is the standard tool for asking whether COPS6 is required for these processes — COPS6 is one of eight subunits of the COP9 signalosome (CSN, CSN1-8 plus accessory subunits), a multi-protein complex with MPN+/JAMM metalloprotease activity (provided by CSN5/COPS5) that deneddylates cullin-RING ligases (CRLs), regulating CRL E3 ligase activity dynamics. COPS6/CSN6 has been characterized as a cancer-relevant CSN component with overexpression in multiple cancers. Overexpression is useful for studying COPS6 in heterologous expression contexts. For ubiquitin biology research, the EDITGENE COPS6 Knockout in HAP1 enables study of CSN-mediated CRL deneddylation. Rescue with wild-type COPS6 is the standard specificity control. The knockout is valuable for studying CRL E3 ligase regulation, MYC/AKT stability (COPS6 has been implicated in regulating MYC and AKT levels in cancer), and emerging CSN-targeted cancer therapeutics.

Yes. COPS6 rescue experiments require attention to CSN complex assembly: • Construct design: use a codon-modified COPS6 sequence with a small C-terminal tag (FLAG, HA). COPS6 has the canonical MPN domain architecture — preserve protein integrity. • CSN complex partnership: COPS6 requires other CSN subunits for stable complex assembly — rescue interpretation considers CSN1-8 expression. • Functional readout: rescue should restore CRL deneddylation activity measured by CUL-NEDD8 vs CUL ratio. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

The choice depends on whether you are studying CD63 (LAMP3, tetraspanin TSPAN30)'s role as a late endosomal/lysosomal tetraspanin or modeling its classical role as an exosome and tumor surface marker. The Knockout line is the standard tool for asking whether CD63 is required for these processes — CD63 is a four-transmembrane tetraspanin highly enriched on late endosomes, lysosomes, and intraluminal vesicles of multivesicular bodies (MVBs), making CD63 one of the most reliable exosome and MVB markers; CD63 also has roles in melanosome biogenesis and platelet activation. Overexpression is useful for studying CD63 in heterologous expression contexts. For exosome research, the EDITGENE CD63 Knockout in THP-1 is highly informative — THP-1 is a human monocytic leukemia cell line providing a myeloid context for studying CD63's role in exosome biogenesis from macrophage-like cells. Other tetraspanin family members (CD9, CD81, CD151) expression analysis aids interpretation. Rescue with wild-type or trafficking-deficient CD63 (Y235A in the AP-3 binding motif) enables structure-function studies. The knockout is valuable for studying CD63-dependent exosome biogenesis and cargo loading, MVB biology, and emerging CD63-targeted approaches in cancer.

Yes. CD63 rescue experiments require attention to late endosomal/lysosomal targeting: • Construct design: use a codon-modified CD63 sequence with a small intracellular C-terminal tag (FLAG, HA). CD63 is a four-transmembrane tetraspanin with C-terminal cytoplasmic GYEVM sequence (YXXΦ AP-3 binding motif) for late endosome/lysosome targeting — preserve all elements. • Subcellular localization validation: confirm late endosomal/lysosomal localization by CD63-LAMP1 co-staining. • Trafficking-deficient rescue: Y235A mutation in the AP-3 binding motif redirects CD63 from late endosomes to plasma membrane. • Functional readout: rescue should restore CD63-positive exosome biogenesis. THP-1-specific considerations: • THP-1 is a human acute monocytic leukemia cell line widely used as a monocyte/macrophage model — PMA differentiation generates adherent macrophage-like cells. • Lentiviral transduction efficiency is moderate; suspension and adherent (post-PMA) phenotypes should be characterized separately. • THP-1 retains key monocyte/macrophage markers and is relevant for monocyte/macrophage exosome and surface marker biology.

The choice depends on whether you are studying CREB1 (cAMP response element-binding protein 1)'s role as the prototypical cAMP/PKA-responsive transcription factor or its functions in learning, memory, and metabolic gene regulation. The Knockout line is the standard tool for asking whether CREB1 is required for these processes — CREB1 is a bZIP transcription factor that binds cAMP response elements (CRE, TGACGTCA) and is phosphorylated at S133 by PKA (downstream of cAMP), CaMK, MSK1, and other kinases; phospho-S133 CREB recruits CBP/p300 coactivators to drive target gene expression including BDNF, c-FOS, NR4A1, PCK1 (gluconeogenesis), and others. Overexpression is useful for studying CREB1 gain-of-function effects. Important consideration: CREB family members (CREB1, CREM, ATF1) share substantial substrate scope as CRE-binding factors — single CREB1 knockout may show modest phenotypes in some contexts if CREM/ATF1 compensate. Rescue with wild-type, S133A (phospho-resistant, transactivation-deficient), or DNA-binding-deficient CREB1 enables comprehensive structure-function studies. The knockout is valuable for studying cAMP-PKA-CREB signaling, learning/memory biology (CREB is critical for long-term memory formation), metabolic transcription (hepatic gluconeogenesis), and emerging CREB-targeted therapeutics in cancer (CREB inhibitors XX-650-23, 666-15) and metabolic disease.

Yes. CREB1 rescue experiments are well-established for transcription factor research: • Construct design: use a codon-modified CREB1 sequence with a small C-terminal tag (FLAG, HA). CREB1 has N-terminal Q1 (glutamine-rich) domain, KID (kinase-inducible domain, with S133 phospho-site), Q2 domain, and C-terminal bZIP (basic region + leucine zipper, DNA binding) — preserve all elements. • Phospho-resistant rescue: S133A mutation abolishes PKA/CaMK/MSK1-mediated phosphorylation and CBP/p300 recruitment, generating signal-insensitive CREB1. • Phospho-mimetic rescue: S133D/E mutations partially mimic phospho-CREB to test constitutively active transcription. • DNA-binding-deficient rescue: bZIP basic region mutations abolish CRE binding without affecting dimerization. • Functional readout: rescue should restore cAMP-induced CRE-reporter activity and target gene (BDNF, c-FOS) induction. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

The choice depends on the experimental question. CHCHD6 (coiled-coil-helix-coiled-coil-helix domain containing 6, MIC25) is a component of the MICOS (mitochondrial contact site and cristae organizing system) complex. The Knockout line is appropriate for asking whether CHCHD6 is required for predicted activities — CHCHD6 is one of multiple CHCHD-domain proteins that participate in MICOS complex assembly with MIC60/CHCHD3 paralogs; MICOS organizes the inner mitochondrial membrane cristae junctions essential for mitochondrial function. Overexpression is useful for studying CHCHD6 in heterologous expression contexts. For mitochondrial biology research, the EDITGENE CHCHD6 Knockout in HAP1 enables study of MICOS biology. Other MICOS components (MIC60/IMMT, MIC19/CHCHD3, MIC25/CHCHD6, MIC10/MICOS10, MIC13, MIC26, MIC27) expression analysis aids interpretation. Rescue with wild-type CHCHD6 is the standard specificity control. The knockout is valuable for studying cristae junction architecture and mitochondrial inner membrane organization.

Yes. CHCHD6 rescue experiments require attention to mitochondrial targeting and MICOS assembly: • Construct design: use a codon-modified CHCHD6 sequence with a small C-terminal tag (FLAG, HA). CHCHD6 has N-terminal mitochondrial targeting sequence and CHCH (twin CX9C) domain — preserve mitochondrial targeting and disulfide bonds. • Mitochondrial localization validation: confirm mitochondrial localization by appropriate compartment markers. • Functional readout: rescue should restore MICOS complex integrity and cristae junction morphology. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

The choice depends on whether you are studying BRCA2's role as the principal RAD51-loading factor for homologous recombination or modeling BRCA2-deficient cancers for PARP inhibitor synthetic lethality. The Knockout line is the standard tool for asking whether BRCA2 is required for these processes — BRCA2 is a critical homologous recombination (HR) repair factor that, together with PALB2 and DSS1, loads RAD51 onto resected single-stranded DNA at double-strand break sites; BRCA2 contains the BRC repeats (RAD51 binding) and DNA-binding domain. BRCA2 germline mutations cause hereditary breast and ovarian cancer syndrome (HBOC) with substantially elevated lifetime cancer risk; BRCA2 is also implicated in Fanconi anemia complementation group D1 (biallelic mutations) and prostate, pancreatic cancer predisposition. Overexpression is useful for studying BRCA2 in heterologous expression contexts. For HR-deficient cancer therapy research, the EDITGENE BRCA2 Knockout in BT-549 is uniquely valuable — BT-549 is a triple-negative breast cancer (TNBC) cell line, providing a clinically relevant context for HR-deficient cancer research. Rescue with wild-type or patient-derived BRCA2 mutations enables disease modeling. The knockout is a critical specificity control for ⭐⭐⭐ PARP inhibitors: ⭐⭐⭐ olaparib (Lynparza), talazoparib (Talzenna), niraparib (Zejula), rucaparib (Rubraca) — the foundational PARP inhibitor class for BRCA-mutated breast, ovarian, prostate, and pancreatic cancers exploiting synthetic lethality.

Yes, with significant technical considerations for this very large protein: • Construct design: BRCA2 is a ~3,418 aa protein (~390 kDa) with 8 BRC repeats (RAD51 binding), DNA-binding domain (DBD), and OB-folds — full-length cDNA rescue is technically challenging due to the >10 kb mRNA size. • Domain-focused rescue: BRC repeat regions or partial BRCA2 constructs may be more tractable for specific functional rescue. • PARP inhibitor sensitivity rescue: WT BRCA2 rescue should restore HR proficiency and PARP inhibitor resistance — provides on-target PARP inhibitor validation. • BRCA2 reversion mutation rescue: clinically observed reversion mutations enable PARP inhibitor resistance mechanism studies. • Functional readout: rescue should restore RAD51 foci formation and IR-induced HR repair. BT-549-specific considerations: • BT-549 is a human triple-negative breast cancer (TNBC) cell line with characteristic basal-like features — relevant for TNBC biology, BRCA-deficient cancer modeling, and PARP inhibitor research. • Lentiviral transduction is supported with moderate efficiency. • BT-549 has TP53 mutation and other features of aggressive TNBC.